Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Core Insights - Geron Corporation reported a net product revenue of $48 million for Q4 2025 and $184 million for the full year 2025, indicating a growth in demand for RYTELO [1][5] - The company ended 2025 with approximately $401 million in cash and marketable securities, down from $503 million in 2024 [4][22] - Geron reiterated its financial guidance for 2026, expecting RYTELO net product revenue between $220 million and $240 million, and total operating expenses between $230 million and $240 million [1][14] Financial Performance - Total product revenue for Q4 2025 was $48 million, compared to $47.5 million in Q4 2024, while full-year revenue increased from $76.5 million in 2024 to $183.6 million in 2025 [7][8] - The company reported a net loss of $31.1 million for Q4 2025, compared to a net loss of $25.4 million in Q4 2024, and a total net loss of $85.8 million for the full year 2025, down from $174.6 million in 2024 [5][6] - Total operating expenses for 2025 were $255 million, slightly above the previous year's $250.7 million [9] Operational Highlights - RYTELO demand grew by 9% in Q4 2025 compared to Q3 2025, with an increase of 150 ordering accounts, bringing the total to approximately 1,300 [5] - The company is focusing on driving U.S. commercial growth and exploring international opportunities for RYTELO, supported by FDA approval and scientific evidence [2][22] - Geron is preparing for the IMpactMF interim analysis in relapsed/refractory myelofibrosis and anticipates initial data from real-world experience trials in lower-risk MDS in the second half of 2026 [2] Cost Management - Research and development expenses decreased to $73.7 million in 2025 from $103.7 million in 2024, primarily due to lower clinical trial costs following RYTELO's approval [11] - Selling, general, and administrative expenses increased to $159.3 million in 2025 from $145.7 million in 2024, attributed to higher sales and marketing investments [12] - Restructuring charges of $17 million were incurred in 2025 due to a workforce reduction of approximately one-third of the staff [13]